A Phase 1, Multi-center, Open-label, Dose-escalating Study to Evaluate the Safety and Tolerability of Triple Combination Regimen of SL-T10, GX-I7 and Pembrolizumab in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Efineptakin alfa (Primary) ; SL T10 (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Bone metastases; Prostate cancer; Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors SL VAXiGEN
- 08 Apr 2024 New trial record